# Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

> **NCT03667482** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Head and Neck Squamous Cell Cancer
- Recurrent Head and Neck Squamous Cell Cancer
- Metastatic Head and Neck Squamous Cell Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03667482
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-07
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03667482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03667482, "Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03667482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*